Linked Life Data

17192135

Source:http://linkedlifedata.com/resource/pubmed/id/17192135

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2006-12-28
pubmed:abstractText
Ramipril is an oral, non-sulfhydryl ACE inhibitor thought to act in the renin-angiotensin-aldosterone system to decrease vasopressor activity, aldosterone secretion, and bradykinin degradation. Ramipril is generally well tolerated and effective in the treatment of patients aged > or =55 years at high risk for the development of cardiovascular (CV) events, in whom the risk of myocardial infarction (MI), stroke, and CV death can be significantly reduced. The risk of these CV outcomes may also be reduced with ramipril therapy in various subgroups; these include patients with diabetes mellitus, peripheral arterial disease (PAD) or renal insufficiency, and women. Thus, ramipril, in addition to lifestyle interventions, should be considered an important therapy in the prevention of CV outcomes in high-risk patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1175-3277
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
417-32
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients.
pubmed:affiliation
Wolters Kluwer Health, Adis, Auckland, New Zealand. demail@adis.co.nz
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Review, Multicenter Study